Lumenis Launches OptiLIFT Stimulation Device

Lumenis Be. Ltd., an energy-based medical device company for eye care and aesthetic solutions, announced the launch of OptiLIFT^™, a new, proprietary Dynamic Muscle Stimulation technology (DMSt^™) for toning facial muscles to address lower lid laxity and impaired blinking without the need for surgery.

ABOUT OptiLIFT

OptiLIFT is the latest innovation by Lumenis, the inventor of OptiLIGHT, the first and only intense pulsed light (IPL) device granted authorization by the FDA for dry eye management. OptiLIFT is now available in the U.S., with other markets expected to follow.

Lower lid laxity is highly prevalent and is associated with the natural aging process, caused in part by the weakening of the orbicularis oculi muscle (OOM).¹ Skeletal muscles lose 3-8% mass each decade after age 30.² Muscle weakening in the periorbital area reduces structural support, which can result in lower lid laxity and incomplete blinking, leading to ocular symptoms and aesthetic concerns.^3,4,5 One study revealed that more than 60% of dry eye patients suffer from impaired lid closure.^6,7 Until now, options to address lower lid laxity and impaired blinking have been limited.

OptiLIFT utilizes Dynamic Muscle Stimulation technology (DMSt^™) to restore muscle tone, resulting in improved function of the lower eyelid and blinking quality. In a new clinical study, led by James Chelnis, MD, FACS, an ophthalmic plastic and reconstructive surgeon at Manhattan Face & Eye, Lumenis’s DMSt^™ demonstrated a reduction in lid laxity by at least 75%, an improvement in blinking quality by at least 70%, and a significant 286% increase in tear break-up time (TBUT).⁸

“Lower lid laxity affects a large number of patients and can play a significant role in creating ocular surface symptoms. Despite this, we have had very few options for addressing it effectively. OptiLIFT finally offers us a non-surgical solution that is effective and comfortable for patients, without any downtime,” says Dr. Chelnis. “Our clinical study revealed remarkable outcomes for patients that highlight the true value of OptiLIFT.”

Specifically designed for treatment of the periorbital area, OptiLIFT’s Dynamic Muscle Stimulation technology works by activating the facial muscles with electrical impulses, tightening and toning the periorbital muscle. The device’s radiofrequency (RF) component precisely delivers heat to skin layers to enhance collagen formation.⁹ OptiLIFT is also available with an optional RF microneedling upgrade, which utilizes ultrathin needles and a double RF mechanism to increase skin smoothness by 80% and triple hyaluronic acid production—offering notable results without downtime or numbing.¹⁰

“We are proud to introduce OptiLIFT, a groundbreaking advancement that addresses a significant and unmet need for patients and practices,” says Itay Mayer, Chief Commercial Officer, Lumenis. “OptiLIFT enables providers to address lower lid laxity and impaired blinking non-surgically, delivering meaningful results for patients while offering a unique opportunity for practice differentiation. We look forward to collaborating with providers to close the gap in their practices, bring this new solution to the market and elevate patient care.”

Lumenis will exhibit OptiLIFT at the upcoming Vision Expo East in Orlando, Florida, later this month. To learn more or receive a trial treatment, attendees can find Lumenis at booth #F1829.

For more information about OptiLIFT, visit https://information.lumenis.com/optilift.

*Warnings and risks: The OptiLIFT System is contraindicated for patients with pacemakers, defibrillators, any implanted electronic device, or metal implanted in the treatment area. Side effects may appear either at the time of treatment or shortly after. Side effects may include any of the following: prolonged or significant pain, damage to natural skin texture (blister, burn), excessive skin redness (erythema), excessive swelling (edema), fragile skin bruising, excessive itching, change of pigmentation (hyper-pigmentation or hypopigmentation), scarring transient skin break-out such as acne and pimples. For a complete list of contraindications, please refer to the User Manual. 

REFERENCES

1. Chhadva, P, AL McClellan, CR Alabiad, WJ Feuer, H Batawi, and A Galor. 2016. “Impact of eyelid laxity on symptoms and signs of dry eye disease.” Cornea 531-535.
2. Volpi E, Nazemi R, Fujita, S. Muscle tissue changes with aging. Current Opinion in Clinical Nutrition and Metabolic Care. 7(4):p 405-410, July 2004. 
3. Chhadva, P, AL McClellan, CR Alabiad, WJ Feuer, H Batawi, and A Galor. 2016. Impact of eyelid laxity on symptoms and signs of dry eye disease. Cornea 531-535.
4. Liu, DTS, MA Di Pascuale, J Sawai, YY Gao, and SC Tseng. 2005. Tear film dynamics in floppy eyelid syndrome. Investigative ophthalmology & visual science 46 (4): 1188-1194.
5. Mastrota, KM. 2008. Impact of floppy eyelid syndrome in ocular surface and dry eye disease. Optom Vis Sci 85: 814-816.
6. Korb D, Blackie C, Nau A. Prevalence of compromised lid seal in symptomatic refractory dry eye patients and asymptomatic patients. Invest Ophthalmol Vis Sci. 2017;58:2696
7. Korb DR, Blackie CA. Treating inadequate lid seal in patients with dry eye using an overnight ointment reduces discomfort upon awakening and overall dry eye symptoms. Invest Ophthalmol Vis Sci. 2016;57(12):6189.
8. Chelnis et al., 2024. Data on file; manuscript under preparation.
9. Haim Kaplan, Andrea Gat, Clinical and histopathological results following TriPollar™ radiofrequency skin treatments Journal of Cosmetic and Laser Therapy 2009; 11: 78–84 DOI: 10.1080/14764170902846227
10. Potekaev N, Zhukova O. Evaluation of Safety and efficacy of the Maximus System for facial wrinkles. Journal of Cosmetics, Dermatological Sciences and Applications, 2013; Vol. 3: 151-156